S-1/A: Cortigent Launches IPO to Fund Brain Implant Development

Cortigent, a pre-revenue neurostimulation company, is pursuing a $15 million IPO to advance its artificial vision and stroke recovery systems, despite ongoing operating losses and a 'going concern' warning.

Summary

• Cortigent, a spin-off from Vivani Medical, Inc. (formerly Second Sight), is conducting an Initial Public Offering (IPO) of 1,500,000 shares of common stock at an anticipated price of $10.00 per share.
• The company aims to raise approximately $13.454 million in net proceeds (or $15.524 million if underwriters exercise their over-allotment option in full) to fund research and development, clinical trials, and repay debt to its parent company, Vivani.
• Cortigent is developing the Orion Visual Cortical Prosthesis System for artificial vision, which has completed a six-year Early Feasibility Study (EFS) with positive safety and efficacy results in a small cohort.
• The Orion system is designed to treat nearly all forms of blindness, with an estimated U.S. total addressable market (TAM) of approximately 82,000 profoundly blind Americans, potentially generating $4 billion in revenue.
• A Stroke Recovery System is also under development, targeting improved arm and hand function in partially paralyzed stroke patients, with an estimated U.S. TAM of 195,000 patients annually, potentially generating $6 billion.
• The company is pre-revenue, reported net losses of $3.1 million in 2025 and $2.2 million in 2024, and has a 'going concern' warning due to recurring operating losses and negative cash flows.
• Vivani Medical, Inc. will remain the controlling shareholder, owning approximately 77% of Cortigent's voting power post-IPO (74% if over-allotment option is fully exercised).
• Cortigent holds an extensive intellectual property estate with 154 issued U.S. patents, 13 issued European patents, and several pending applications, covering neurostimulation techniques and implant longevity.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the company's pre-revenue status, significant recurring operating losses, and an explicit 'going concern' warning. While the technology shows promise and has received FDA Breakthrough Device designation for Orion, the substantial capital requirements, regulatory hurdles, and competitive landscape present high risks for investors.

Positives

• The Orion Visual Cortical Prosthesis System received FDA Breakthrough Device designation in 2018, which is intended to accelerate development and review.
• The Orion Early Feasibility Study (EFS) showed positive efficacy results: at 36 months, 5 of 6 subjects performed significantly better on square localization and direction of motion with the system on, and 2 had measurable visual acuity.
• At 60 months, the 3 remaining subjects in the Orion EFS continued to perform significantly better on square localization and direction of motion, and 2 had measurable visual acuity.
• The Functional Low-Vision Observer Rated Assessment (FLORA) indicated positive or mildly positive benefits for all four subjects who completed the 36-month evaluation.
• The estimated U.S. total addressable market for Orion is approximately 82,000 profoundly blind individuals, potentially a $4 billion market, significantly larger than the previous Argus II system.
• The estimated U.S. total addressable market for the Stroke Recovery System is approximately 195,000 stroke victims annually, potentially a $6 billion market.
• Cortigent possesses an extensive intellectual property portfolio with 154 issued U.S. patents and 13 issued European patents, with some extending into 2038, covering core neurostimulation technologies.
• The company's neurostimulation platform technology has multiple potential applications beyond vision and stroke recovery, offering future growth opportunities.

Negatives

• Cortigent is a pre-revenue company with a history of recurring operating losses, reporting a net loss of $3.1 million in 2025 and $2.2 million in 2024.
• The company's financial statements include a 'going concern' warning, indicating substantial doubt about its ability to continue operations without additional financing.
• The FDA denied Breakthrough Device designation for the Stroke Recovery System in June 2023, which could lead to slower interactions with the FDA and delayed development timelines.
• Three of the six subjects in the Orion EFS requested explantation of their devices, although reasons were determined to be unrelated to device safety or efficacy, it limits long-term data.
• The company has limited staff (six full-time employees as of February 27, 2026) and will require substantial additional capital to fund clinical trials and growth plans.
• Approximately 100 of Cortigent's issued U.S. patents will reach the end of their term by the end of 2029, potentially reducing intellectual property protection.
• Cortigent has no large-scale manufacturing experience and relies on sole-source suppliers for critical components, posing risks to production scale-up and costs.
• The company needs to reestablish its ISO 13485:2016 certification and CE mark certification to market products in Europe, which have lapsed.

Risks

• Cortigent currently has no commercial products or product revenue and may never become profitable.
• Commercial and financial success depends on future products being accepted in the market, which is uncertain.
• Substantial competition from major medical device companies, academic institutions, and research institutions is expected.
• Results of limited initial trials may not be predictive of future trial results, and commercial feasibility of Orion or other technologies may not be demonstrated.
• Clinical development of complex implantable medical devices is a lengthy, expensive process with uncertain outcomes.
• Interim top-line and preliminary clinical trial results may change as more patient data becomes available and are subject to audit and verification.
• Substantial additional capital is required to support clinical trials and growth plans, and may not be available on acceptable terms, if at all.
• Future capital raises through equity or debt may dilute existing stockholders and new securities may have senior rights.
• The company may be subject to litigation, governmental inspections, investigations, and inquiries, which could adversely affect the business.
• Any failure or delay in completing clinical trials or studies for new product candidates could adversely affect the business.
• Failure to recruit highly skilled personnel could impair the ability to develop and commercialize new products.
• Inability to protect intellectual property could adversely affect financial condition and product value.
• Litigation or third-party claims of intellectual property infringement or challenges to patent validity could prevent or delay development and commercialization.
• Failure to comply with obligations in third-party licensing agreements could result in loss of important license rights.
• Dependence on sophisticated information technology systems and third-party vendors, with risks of data integrity failure or product malfunction.
• Product liability lawsuits could divert resources, result in substantial liabilities, and reduce commercial potential.
• Legislative or regulatory reform of the healthcare system in the U.S. and foreign jurisdictions may adversely impact business.
• Stringent domestic and foreign medical device regulation, with unfavorable regulatory action materially and adversely affecting financial condition.
• Revenue from product sales is dependent on pricing and reimbursement guidelines, and inadequate levels could cause operations to suffer.
• Ongoing regulatory requirements and inspections could lead to restriction, suspension, or revocation of product clearance or approval.
• Lack of large-scale manufacturing experience could limit growth.
• The price of common stock may be volatile, and investment value could decline.
• No prior trading market for securities, and stock price may decline after the offering.
• Management has broad discretion in the use of proceeds, which may differ from estimates.
• New investors will experience immediate and substantial dilution due to the offering price being higher than pro forma net tangible book value.
• The right to issue preferred stock could adversely affect common stock rights and have anti-takeover effects.
• Future sales and issuances of equity securities would result in dilution and could cause stock price to fall.
• Provisions in the Certificate of Incorporation regarding exclusive forum for disputes could limit stockholders' ability to obtain a favorable judicial forum.
• Increased costs will be incurred as a result of being a publicly traded company.
• Economic downturns and geopolitical instability could adversely affect business, financial condition, and prospects.
• Reliance on government funding and collaboration with government entities adds uncertainty and may impose requirements that increase costs.

Future Outlook

Cortigent plans to commence a pivotal clinical trial for the Orion system in late 2027, expecting completion by late 2029 and a U.S. launch in 2030, contingent on FDA clearance and adequate financing. A Stroke Early Feasibility Study is planned in parallel for late 2027, with a pivotal trial for the Stroke Recovery System targeted for early 2029, completion by late 2030, and commercial launch in 2031. The company intends to reapply for a Breakthrough Device designation for the Stroke Recovery System once clinical data is available and plans to reapply for NIH grant funding in early 2026. The success of these timelines is subject to FDA discussions and securing sufficient financing.

Management Comments

• "We believe that our 20-year history in developing neurostimulation for artificial vision with the Argus II system positions us well for expanded neurostimulation applications such as Orion and the stroke recovery system."
• "We believe that our 60-channel cortical stimulation device has the potential to target neuron populations more precisely and generate favorable clinical results (for stroke recovery)."
• "We believe that about one-third of these patients (Orion's TAM) could be reached by a marketing program."
• "We believe that outside the United States there are substantially more blind people who could potentially benefit from Orion (Europe, Asia, and the rest of the world)."
• "We expect that our technology has the potential to deliver more targeted direct cortical stimulation that could provide comparatively superior results (for stroke recovery) than competitors."
• "We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees."
• "We believe that our success will also be rooted in the diversity of our teams and our commitment to inclusion."

Industry Context

StockSavvy.ai notes that Cortigent operates in the highly competitive and rapidly evolving neurostimulation and medical device industry. While Cortigent's Orion system, a surface-implanted cortical prosthesis, currently has no direct FDA-approved competitors for broad blindness indications, several companies are developing alternative visual prostheses. Science Corp. is pursuing a sub-retinal implant for Dry-AMD in Europe, and Bionic Vision Technologies is developing a Bionic Eye Visual Prosthesis System in Australia. More notably, companies like Illinois Institute of Technology and ReVision Implant are developing penetrating brain electrode arrays for vision, and Neuralink Corp. has received FDA Breakthrough Device Designation for its Blindsight vision restoration program, which also involves cortical stimulation, though its current clinical efforts emphasize neural activity recording. In stroke rehabilitation, MicroTransponder Inc. offers the FDA-approved Vivistim VNS, and Enspire DBS Therapy, Inc. is conducting a pivotal trial for Deep Brain Stimulation (DBS) targeting the cerebellum. Cortigent's strategy of direct cortical stimulation with a 60-channel device aims to offer more precise targeting compared to VNS or single-channel devices, but faces significant hurdles in a landscape with well-funded and established competitors, some of whom are also pursuing Breakthrough Device designations.

Comparison to Industry Standards

• Cortigent's Orion system, a cortical (brain surface) implant, is designed to treat nearly all forms of blindness, including glaucoma, diabetic retinopathy, and retinitis pigmentosa, with an estimated U.S. TAM of 82,000 profoundly blind Americans and a potential $4 billion market. This is a broader target than its predecessor, Argus II, which was limited to retinitis pigmentosa (less than 8,000 patients).
• Competitors like Science Corp. (acquired Pixium Vision SA assets) are developing sub-retinal implants (PRIMA) primarily for Dry-AMD patients, with an application filed for EU approval in June 2025. This targets a different patient population and uses a different implant location.
• Bionic Vision Technologies (Australia) is developing a Bionic Eye Visual Prosthesis System and has completed a two-year feasibility study in seven patients, indicating a similar stage of early clinical development for vision restoration.
• The Illinois Institute of Technology's Intracortical Visual Prosthesis (ICVP) and ReVision Implant (Belgium) are developing electrode arrays that *penetrate* the brain, contrasting with Cortigent's surface implant approach. ICVP has advanced to an early feasibility study with two of five patients implanted, while ReVision Implant anticipates human implants in 2026.
• Neuralink Corp. has received FDA Breakthrough Device Designation for its Blindsight vision restoration program, which also involves cortical stimulation but uses penetrating electrodes (N1 implant). Neuralink has publicly demonstrated device control in paralyzed individuals and reported no serious device-related adverse events to date in its broader BCI clinical trials (21 participants globally as of January 2026). Cortigent's focus is on patterned electrical stimulation for restoration, while Neuralink's disclosed efforts have emphasized recording and decoding neural activity.
• For stroke recovery, Cortigent's proposed system aims for targeted direct cortical stimulation. This contrasts with MicroTransponder Inc.'s Vivistim (FDA-approved vagus nerve stimulator, VNS) which combines VNS with rehabilitation, and Enspire DBS Therapy, Inc.'s Deep Brain Stimulation (DBS) system (RESTORE trial, 40 pilot subjects, 162 pivotal subjects, expected completion June 2030) which targets the dentate nucleus of the cerebellum. Cortigent believes its 60-channel cortical stimulation offers superior precision.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not party to any material legal proceedings.
• May be involved in legal proceedings or subject to claims incident to the ordinary course of business in the future.
• Vivani has chosen to indemnify Cortigent for certain claims from the former business prior to August 30, 2022.

Related Party Transactions

• Cortigent was formed as a wholly owned subsidiary of Vivani Medical, Inc. in November 2022, with Vivani contributing all of Second Sight's neurostimulation assets and operations.
• Vivani guaranteed the lease for Cortigent's office space, effective March 1, 2023.
• Vivani entered into a Transition Funding, Support and Services Agreement in March 2023 (amended August 2023) to advance funds and provide services to Cortigent, covering salaries, rent, and overhead.
• Cortigent is required to repay $1.5 million from the IPO proceeds to Vivani and issue a five-year promissory note for $2 million at 5% annual interest upon maturity.
• Vivani agreed that Cortigent is not obligated to repay additional funding support payments exceeding $3.5 million.
• Vivani continues to provide operational funding to Cortigent through the completion of the IPO.
• Vivani provides the services of its Chief Operating Officer (Truc Le) and Chief Business Officer (Donald Dwyer) to Cortigent on an interim basis.
• Cortigent provides the services of its Chief Financial Officer (Edward Sedo) to Vivani.
• Vivani will beneficially own approximately 77% of Cortigent's voting power post-IPO (74% if over-allotment exercised), maintaining control over stockholder matters.
• A master separation agreement will restrict Cortigent from certain actions (e.g., incurring additional indebtedness, acquiring/disposing of assets above certain amounts) without Vivani's prior written consent, as long as Vivani owns at least 50% of voting power.

Stakeholder Impact

• **Shareholders (Existing & New):** Existing shareholders (Vivani) will experience dilution from the IPO. New investors will face immediate and substantial dilution ($8.51 per share) as the IPO price is significantly higher than the pro forma net tangible book value. Vivani's continued majority ownership means it will control all matters requiring stockholder approval, potentially aligning with its own interests over other shareholders.
• **Employees:** The company currently has only six full-time employees. Future growth and success depend on the ability to attract and retain highly skilled personnel. The 2023 equity incentive plan aims to provide future value to employees, consultants, and directors.
• **Customers/Patients:** Potential customers (profoundly blind individuals, stroke patients) stand to benefit from the successful development and commercialization of the Orion and Stroke Recovery Systems, offering novel treatments for high unmet medical needs. However, the investigational nature of the devices means no assurance of safety, efficacy, or commercial availability.
• **Suppliers:** Reliance on sole-source suppliers for critical components creates a risk of delays and increased costs if these suppliers are unable to deliver or if alternative suppliers cannot be qualified.
• **Creditors:** The 'going concern' warning and recurring operating losses indicate a high financial risk, which could impact the company's ability to secure future debt financing on favorable terms.

Next Steps

• Manufacture and validate new Orion devices for a planned pivotal clinical trial.
• Commence the Orion pivotal clinical trial in late 2027, involving approximately 60 profoundly blind patients at 10 U.S. trial sites.
• Complete the Orion pivotal trial by late 2029 and, if successful, launch Orion in the U.S. in 2030.
• Conduct a Stroke Early Feasibility Study (Stroke EFS) in parallel with Orion device manufacturing in late 2027.
• Commence a pivotal clinical trial for the Stroke Recovery System in early 2029, contingent on Stroke EFS outcomes.
• Complete the Stroke Recovery System pivotal trial by late 2030 and, if successful, commercially launch in 2031.
• Reapply for NIH grant funding in early 2026 to support the Stroke Recovery System program.
• Reapply for Breakthrough Device designation for the Stroke Recovery System once clinical data supporting the novel approach are acquired.
• Work with the FDA to gain agreement on additional clinical studies and safety endpoints for Orion and the Stroke Recovery System.
• Conduct a patient preference information (PPI) study for Orion to assist in determining blind patients' willingness to accept risk.
• Engage two U.S.-based contract manufacturing organizations (CMOs) for Orion and Stroke Recovery System production after completing the current offering.
• Reestablish ISO 13485:2016 certification and CE mark certification to market products in Europe.

Key Dates

Recommendation

Cortigent is a pre-revenue company with a history of significant operating losses and an explicit 'going concern' warning from its auditors. While its neurostimulation technology for artificial vision and stroke recovery is innovative and addresses large unmet medical needs, the path to commercialization is lengthy, expensive, and highly uncertain, requiring substantial additional capital beyond this IPO. The FDA's denial of Breakthrough Device designation for the Stroke Recovery System and the need to reestablish European certifications highlight significant regulatory hurdles. New investors face immediate and substantial dilution, and the controlling ownership by Vivani may lead to potential conflicts of interest. Given the high financial risk, lack of current revenue, and long development timelines, a 'sell' recommendation is appropriate for investors seeking a more stable risk-reward profile.

Keywords

Neurostimulation, Brain Implants, Artificial Vision, Stroke Recovery, Medical Devices, FDA Breakthrough Device, IPO, Biotechnology, Ophthalmology, Neurology, Cortical Prosthesis, Retinitis Pigmentosa, Glaucoma, Diabetic Retinopathy, Motor Impairment